Colchicine Transdermal Patch Matrix for Safer Therapeutic Permeation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Colchicine has a small treatment safety window and low bioavailability due to the first-pass effect in the liver, leading to significant side effects and low patient compliance in oral administration, and existing transdermal delivery systems have not adequately addressed these issues.

Innovation Solution

A patch containing colchicine with a polymer matrix layer comprising 0.1%-5.0% colchicine, 0.005%-15% permeation enhancer, and 80%-99% pressure-sensitive adhesive, which includes a backing layer to protect the matrix and prevent drug loss, and a permeation enhancer that promotes controlled transdermal permeation without skin irritants.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If oral colchicine is administered to achieve therapeutic effect, then the treatment effectiveness is improved, but serious side effects such as gastrointestinal irritation, bone marrow suppression, and arrhythmia occur

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a transdermal delivery system as an intermediary between the colchicine drug and the patient's body. The patch delivers colchicine directly through the skin into systemic circulation, bypassing the gastrointestinal tract and liver first-pass metabolism. This intermediary delivery route eliminates gastrointestinal irritation and reduces hepatic burden, thereby maintaining treatment effectiveness while significantly reducing side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the traditional oral administration route (mechanical ingestion and gastrointestinal processing) with a transdermal delivery system. The patch uses controlled diffusion and permeation through the skin barrier to deliver the drug, substituting the mechanical gastrointestinal absorption process with a controlled transdermal transport mechanism. This substitution avoids gastrointestinal irritation and first-pass metabolism, reducing side effects while maintaining therapeutic effectiveness.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If oral colchicine is administered to achieve therapeutic effect, then the treatment effectiveness is improved, but bioavailability is reduced due to first-pass effect in the liver

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidbioavailability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The transdermal patch serves as an intermediary delivery system that bypasses the liver's first-pass metabolism. By delivering colchicine directly through the skin into systemic circulation, the patch avoids hepatic degradation that would otherwise reduce bioavailability. This intermediary route ensures more of the administered drug reaches systemic circulation in its active form, improving bioavailability while maintaining treatment effectiveness.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Object-affected harmful factors

If transdermal delivery system is used to deliver colchicine, then gastrointestinal side effects are avoided, but adequate transdermal permeation amount is difficult to achieve

Engineering Contradiction:

Improvegastrointestinal side effectsVSAvoidtransdermal permeation amount

Core Design Contradiction:

Object-affected harmful factorsVSQuantity of substance

Solution Approach 1:

The patent optimizes multiple parameters of the transdermal delivery system to achieve adequate permeation. This includes selecting appropriate pressure-sensitive adhesive materials with optimal viscosity and tack properties, adjusting the colchicine concentration within the adhesive matrix, controlling the patch thickness and composition, and optimizing the permeation enhancer content. By carefully adjusting these parameters, the system achieves sufficient transdermal flux to deliver therapeutic doses while maintaining the advantage of avoiding gastrointestinal side effects.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The patch achieves effective transdermal permeation of colchicine with no local irritants or gastrointestinal side effects, ensuring high patient compliance and controlled drug delivery.

Implementation Method 1

a permeation enhancer that promotes controlled transdermal permeation

Methodology Applied

Scientific EffectPermeation: Permeation

Implementation Method 2

80%-99% pressure-sensitive adhesive

Methodology Applied

Scientific EffectAdhesion: Adhesive

Data Source

PatentUS20260014095A1Patch containing colchicine and preparation method and use thereof

Publication Date: 2026.01.15 DEMOTECH INC

AI summary

Provided are a patch containing colchicine, a preparation method and a use thereof, where the patch includes a polymer matrix layer. The polymer matrix layer includes the following components in weight percentage: 0.1%-5.0% of colchicine, 0.005%-15% of a permeation enhancer, and 80%-99% of a pressure-sensitive adhesive. The patch containing colchicine can achieve transdermal permeation of an amount sufficient for achieving treatment effect, and features no local irritant during pasting and after pasting, no gastrointestinal side effects, and high patient compliance.